Literature DB >> 35849783

Single-Cell Sequencing Reveals Trajectory of Tumor-Infiltrating Lymphocyte States in Pancreatic Cancer.

Aislyn Schalck1,2, Donastas Sakellariou-Thompson3,4, Michael P Kim5, Nicholas E Navin1,2,6, Chantale Bernatchez3,4, Marie-Andrée Forget3,4, Emi Sei1, Tara G Hughes1, Alexandre Reuben7, Shanshan Bai1, Min Hu1, Tapsi Kumar1,2, Mark W Hurd8, Matthew H G Katz5, Ching-Wei D Tzeng5, Shubham Pant9, Milind Javle9, David R Fogelman9, Anirban Maitra2,8,10, Cara L Haymaker11.   

Abstract

Pancreatic ductal adenocarcinoma (PDAC) has few effective treatments. Immunotherapy, an attractive alternative strategy, remains challenging with the lack of knowledge on the tumor-infiltrating lymphocyte (TIL) landscape in PDAC. To generate a reference of T-cell subpopulations, we profiled 80,000 T cells from 57 PDAC samples, 22 uninvolved/normal samples, and cultured TIL using single-cell transcriptomic and T-cell receptor analysis. These data revealed 20 cell states and heterogeneous distributions of TIL populations. The CD8+ TIL contained a putative transitional GZMK+ population based on T-cell receptor clonotype sharing, and cell-state trajectory analysis showed similarity to a GZMB+PRF1+ cytotoxic and a CXCL13+ dysfunctional population. Statistical analysis suggested that certain TIL states, such as dysfunctional and inhibitory populations, often occurred together. Finally, analysis of cultured TIL revealed that high-frequency clones from effector populations were preferentially expanded. These data provide a framework for understanding the PDAC TIL landscape for future TIL use in immunotherapy for PDAC. SIGNIFICANCE: To improve the efficacy of immunotherapy in PDAC, there is a great need to understand the PDAC TIL landscape. This study represents a reference of PDAC TIL subpopulations and their relationships and provides a foundation upon which to base future immunotherapeutic efforts. This article is highlighted in the In This Issue feature, p. 2221. ©2022 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35849783      PMCID: PMC9547957          DOI: 10.1158/2159-8290.CD-21-1248

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   38.272


  65 in total

Review 1.  The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis.

Authors:  Ezzeldin M Ibrahim; Meteb E Al-Foheidi; Mubarak M Al-Mansour; Ghieth A Kazkaz
Journal:  Breast Cancer Res Treat       Date:  2014-11-01       Impact factor: 4.872

Review 2.  Pancreatic cancer.

Authors:  Jorg Kleeff; Murray Korc; Minoti Apte; Carlo La Vecchia; Colin D Johnson; Andrew V Biankin; Rachel E Neale; Margaret Tempero; David A Tuveson; Ralph H Hruban; John P Neoptolemos
Journal:  Nat Rev Dis Primers       Date:  2016-04-21       Impact factor: 52.329

3.  Lineage tracking reveals dynamic relationships of T cells in colorectal cancer.

Authors:  Lei Zhang; Xin Yu; Liangtao Zheng; Yuanyuan Zhang; Yansen Li; Qiao Fang; Ranran Gao; Boxi Kang; Qiming Zhang; Julie Y Huang; Hiroyasu Konno; Xinyi Guo; Yingjiang Ye; Songyuan Gao; Shan Wang; Xueda Hu; Xianwen Ren; Zhanlong Shen; Wenjun Ouyang; Zemin Zhang
Journal:  Nature       Date:  2018-10-29       Impact factor: 49.962

4.  Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial.

Authors:  Gregory L Beatty; Mark H O'Hara; Simon F Lacey; Drew A Torigian; Farzana Nazimuddin; Fang Chen; Irina M Kulikovskaya; Michael C Soulen; Maureen McGarvey; Anne Marie Nelson; Whitney L Gladney; Bruce L Levine; J Joseph Melenhorst; Gabriela Plesa; Carl H June
Journal:  Gastroenterology       Date:  2018-03-20       Impact factor: 22.682

5.  Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma.

Authors:  Richard E Royal; Catherine Levy; Keli Turner; Aarti Mathur; Marybeth Hughes; Udai S Kammula; Richard M Sherry; Suzanne L Topalian; James C Yang; Israel Lowy; Steven A Rosenberg
Journal:  J Immunother       Date:  2010-10       Impact factor: 4.456

Review 6.  Regulatory T cells in cancer immunosuppression - implications for anticancer therapy.

Authors:  Yosuke Togashi; Kohei Shitara; Hiroyoshi Nishikawa
Journal:  Nat Rev Clin Oncol       Date:  2019-06       Impact factor: 66.675

7.  Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq.

Authors:  Itay Tirosh; Benjamin Izar; Sanjay M Prakadan; Marc H Wadsworth; Daniel Treacy; John J Trombetta; Asaf Rotem; Christopher Rodman; Christine Lian; George Murphy; Mohammad Fallahi-Sichani; Ken Dutton-Regester; Jia-Ren Lin; Ofir Cohen; Parin Shah; Diana Lu; Alex S Genshaft; Travis K Hughes; Carly G K Ziegler; Samuel W Kazer; Aleth Gaillard; Kellie E Kolb; Alexandra-Chloé Villani; Cory M Johannessen; Aleksandr Y Andreev; Eliezer M Van Allen; Monica Bertagnolli; Peter K Sorger; Ryan J Sullivan; Keith T Flaherty; Dennie T Frederick; Judit Jané-Valbuena; Charles H Yoon; Orit Rozenblatt-Rosen; Alex K Shalek; Aviv Regev; Levi A Garraway
Journal:  Science       Date:  2016-04-08       Impact factor: 47.728

8.  Expansion of Tumor-reactive T Cells From Patients With Pancreatic Cancer.

Authors:  Qingda Meng; Zhenjiang Liu; Elena Rangelova; Thomas Poiret; Aditya Ambati; Lalit Rane; Shanshan Xie; Caroline Verbeke; Ernest Dodoo; Marco Del Chiaro; Matthias Löhr; Ralf Segersvärd; Markus J Maeurer
Journal:  J Immunother       Date:  2016 Feb-Mar       Impact factor: 4.456

9.  The prognostic value of tumor-infiltrating T lymphocytes in ovarian cancer.

Authors:  Jun Li; Jieyu Wang; Ruifang Chen; Yang Bai; Xin Lu
Journal:  Oncotarget       Date:  2017-02-28

10.  Developmental plasticity allows outside-in immune responses by resident memory T cells.

Authors:  Raissa Fonseca; Lalit K Beura; Clare F Quarnstrom; Hazem E Ghoneim; Yiping Fan; Caitlin C Zebley; Milcah C Scott; Nancy J Fares-Frederickson; Sathi Wijeyesinghe; Emily A Thompson; Henrique Borges da Silva; Vaiva Vezys; Benjamin Youngblood; David Masopust
Journal:  Nat Immunol       Date:  2020-02-17       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.